文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

强化预处理方案未能改善高危AML/MDS异基因移植结局

Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
PubMed 文献 · J Clin Oncol · 2020-12-29

移植前MFC-MRD阳性与复发增加相关,3个月获得完全供者T细胞嵌合可消除MRD不良影响。

要点

  • FLAMSA-Bu强化预处理未改善高危AML/MDS移植后2年OS或复发率。
  • 移植前MFC-MRD阳性者2年累积复发率41.0% vs 20.0%。
  • 3个月获得完全供者T细胞嵌合可消除移植前MRD的不良影响。

核心结论

  • 强化RIC方案FLAMSA-Bu未改善高危AML或MDS成人移植结局,无论移植前MRD状态。
  • 数据支持探索加速获得完全供者T细胞嵌合的干预策略以改善AML移植结局。

研究设计与样本

  • 移植前通过流式细胞术监测可测量残留病(MFC-MRD)并与结局关联。

主要发现

  • 对照组与FLAMSA-Bu组2年总生存无差异(HR 1.05 [85% CI, 0.80 to 1.38] P = .81)。
  • 两组累积复发率无差异(HR 0.94 [95%CI, 0.60 to 1.46] P = .81)。
  • 整体队列中移植前MFC-MRD可检测与累积复发率增加相关(2年CIR 41.0% v 20.0%,P = .01)。
  • MRD状态与预处理强度对复发或生存无交互作用证据。
  • 3个月获得完全供者T细胞嵌合消除了移植前MRD对CIR和OS的不良影响。

临床怎么用

  • 高危AML/MDS异基因移植时,不应常规采用FLAMSA-Bu强化预处理以期降低复发。
  • 移植前MFC-MRD阳性提示复发风险增高,需加强监测。
  • 促进移植后早期完全供者T细胞嵌合可能改善MRD阳性患者结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Reduced-intensity conditioning (RIC) regimens have extended the curative potential of allogeneic stem-cell transplantation to older adults with high-risk acute myeloid leukemia (AML) and myelodysplasia (MDS) but are associated with a high risk of disease relapse. Strategies to reduce recurrence are urgently required. Registry data have demonstrated improved outcomes using a sequential transplant regimen, fludarabine/amsacrine/cytarabine-busulphan (FLAMSA-Bu), but the impact of this intensified conditioning regimen has not been studied in randomized trials. PATIENTS AND METHODS: Two hundred forty-four patients (median age, 59 years) with high-risk AML (n = 164) or MDS (n = 80) were randomly assigned 1:1 to a fludarabine-based RIC regimen or FLAMSA-Bu. Pretransplant measurable residual disease (MRD) was monitored by flow cytometry (MFC-MRD) and correlated with outcome. RESULTS: There was no difference in 2-year overall survival (hazard ratio 1.05 [85% CI, 0.80 to 1.38] P = .81) or cumulative incidence of relapse (CIR) (hazard ratio 0.94 [95%CI, 0.60 to 1.46] P = .81) between the control and FLAMSA-Bu arms. Detectable pretransplant MFC-MRD was associated with an increased CIR (2-year CIR 41.0% v 20.0%, P = .01) in the overall trial cohort with a comparable prognostic impact when measured by an unsupervised analysis approach. There was no evidence of interaction between MRD status and conditioning regimen intensity for relapse or survival. Acquisition of full donor T-cell chimerism at 3 months abrogated the adverse impact of pretransplant MRD on CIR and overall survival. CONCLUSION: The intensified RIC conditioning regimen, FLAMSA-Bu, did not improve outcomes in adults transplanted for high-risk AML or MDS regardless of pretransplant MRD status. Our data instead support the exploration of interventions with the ability to accelerate acquisition of full donor T-cell chimerism as a tractable strategy to improve outcomes in patients allografted for AML.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Craddock C, Jackson A, Loke J, et al. Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia. J Clin Oncol. 2020. PMID: 33373276. doi:10.1200/JCO.20.02308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。